medsurfnews - allergology - omalizumab-associated anaphylaxis: joint task force recommendations still good to go

Allergology

Omalizumab-associated anaphylaxis: Joint task force recommendations still good to go

The American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology's (ACAAI) omalizumab joint task force (OJTF) has been monitoring omalizumab-associated anaphylaxis for the past 4 years. In the original report published in a recent issue of The Journal of Allergy and Clinical Immunology, the OJTF found that anaphylaxis occurred in approximately 0.09% of patients receiving omalizumab (an anti-asthma medication), with the majority of the reactions occurring within the first 2 hours after the first 3 injections.
Read more

http://feedproxy.google.com/~r/AaaaiJaciMedia/~3/O_IVNwCSFIw...

American Academy of Allergy, Asthma and Immunology

Last resources from American Academy of Allergy, Asthma and Immunology

Acetylsalicylic acid sensitivity in patients with nasal polyps (Allergology)
Allergen-specific immunotherapy reduced to three injections (Allergology)
Methacholine challenge - a good test to diagnose asthma? (Pneumology)
Impulse oscillometry (IOS) identifies uncontrolled asthma in children (Pneumology)
Familial asthma risk and infant respiratory infection etiology and severity (Pneumology)
View all resources from American Academy of Allergy, Asthma and Immunology